Harris et al reported the TRAIL model for evaluating a patient with diffuse large B-cell lymphoma (DLBCL). This can predict the tolerability of immunochemotherapy for the patient. The authors are from Genentech, Imperial College Healthcare NHS Trust, Aalborg University Hospital and Hoffmann-La Roche.
Patient selection: diffuse large B-cell lymphoma
Immunochemotherapy: CHOP with rituximab or obinutuzumab
Parameters:
(1) creatinine clearance in mL per min
(2) serum albumin in g/L
(3) Charlson Comorbidity Index (CCI)
(4) history of heart disease, vascular disease or diabetes
Parameter
Points
creatinine clearance
86.8 * (1 / (creatinine clearance))
serum albumin
-2.48 * LN(albumin)
Charlson Comorbidity Index
0.170 * (CCI)
comorbidities
0.362 if present; 0 if absent
value of X =
= SUM(points for all of the parameters) + 5.45
probability of being unable to tolerate CHOP in combination with ritixumab or obinutuzumab =
= 1 / (1 + EXP((-1) * X))
To read more or access our algorithms and calculators, please log in or register.
